"Protocol designed for a head-to-head study in animals..." CZO has conducted in vitro studies and demonstrated 5X more binding capacity to the dectin-1a receptor with PGX-YBG yielding 5X more immune stimulative. This could mean a fraction of the dose is required to achieve the same level of immune stimulation. The next step, refered to in the last news release, is to test PGX-YBG in an animal model in a head-to-head study against the competition.
"Protocol designed for a head-to-head study in animals for testing immune properties of PGX-YBG against a commercial formulation." CZO news release
Does PGX-YBG require a much smaller dose to yield the same immuno-stimulatory result? Theoretically if one can use 1/5 the dose to achieve the same result one could require a fraction of the manufacturing costs of the competition and take the $1 billion market? PGX-YBG can also remove impurites and leave the beta glucan closer to its natural state. It could be the gold standard in terms of quality. It is small enough to get inside of macrophages. It can be used as a carrier for other bioactives potentilaly strengthening/complementing its immune stimulative properties. Getting the full immune stimulating properties of PGX-YBG in an animal model in a head-to-head against the competition, and the required dose could be interesting. Again, yeast beta glucan is a billion dollar established market in the much, much bigger immune stimulation market. Lowest dose with the highest quality could be very interesting and CZO could have demonstrated commercial-scale capacity next year with the 10X PGX scale-up. CZO also has the only inhalable yeast beta glucan.